[Federal Register Volume 64, Number 227 (Friday, November 26, 1999)]
[Rules and Regulations]
[Page 66382]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-30701]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520


Oral Dosage Form New Animal Drugs; Lincomycin Soluble Powder

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of an abbreviated new animal drug 
application (ANADA) filed by Alpharma Inc. The ANADA provides for use 
of lincomycin hydrochloride soluble powder to make medicated drinking 
water for swine for the treatment of dysentery (bloody scours) and for 
broiler chickens for the control of necrotic enteritis.

EFFECTIVE DATE: November 26, 1999.

FOR FURTHER INFORMATION CONTACT: Lonnie W. Luther, Center for 
Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-0209.

SUPPLEMENTARY INFORMATION: Alpharma Inc., One Executive Dr., P.O. Box 
1399, Fort Lee, NJ 07024, filed ANADA 200-233 that provides for use of 
Linco Soluble (lincomycin hydrochloride soluble powder) to make 
medicated drinking water for swine for the treatment of dysentery 
(bloody scours) and for broiler chickens for the control of necrotic 
enteritis caused by Clostridium perfringens susceptible to lincomycin.
    The ANADA is approved as a generic copy of Pharmacia & Upjohn's 
NADA 111-636 Lincomix Soluble Powder. ANADA 200-233 is 
approved as of September 22, 1999, and 21 CFR 520.1263c(b) is amended 
to reflect the approval. The basis of approval is discussed in the 
freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
data and information submitted to support approval of this application 
may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, 
between 9 a.m. and 4 p.m., Monday through Friday.
    The agency has determined under 21 CFR 25.33(a)(1) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 520

    Animal drugs.
    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

    1. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.


Sec. 520.1263c   [Amended]

    2. Section 520.1263c Lincomycin hydrochloride soluble powder is 
amended in paragraph (b) by adding at the end the sentence ``Approval 
for use of 40-gram packet to No. 046573 in Sec. 510.600(c) of this 
chapter''.

    Dated: November 10, 1999.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 99-30701 Filed 11-24-99; 8:45 am]
BILLING CODE 4160-01-F